BridgeBio Oncology Therapeutics Reports Q3 GAAP EPS of -$0.43, Exceeding Estimates
BridgeBio Oncology Therapeutics (BBOT) reported third-quarter GAAP earnings per share of -$0.43, which outperformed analyst expectations by $0.26. Despite the net loss, the company's financial position remains stable following its recent quarterly reporting period. As of September 30, 2026, the company held $315.3 million in cash, cash equivalents, and marketable securities. Management expects this liquidity to provide a sufficient cash runway to support operations into 2029.
Tickers: $BBOT
Topics: cash runway earnings beat financial results
Read the full article at Seeking Alpha
Part of the story Altimmune Reports Q3 GAAP EPS of -$0.15, Missing Estimates by $0.02 (3 articles)